[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570072":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":27,"locations":33,"responsibleParty":46,"collaborators":26,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":26,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":26,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":36,"whyStopped":26,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Fayoum University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"The dexmedetomidine","ACTIVE_COMPARATOR","29 patients will receive a bolus dose of dexmedetomidine (0.5 μg kg-1) over 10 minutes before induction followed by an infusion (0.3 μg kg-1 h-1), which will be discontinued at the skin closure.",[13],"Drug: dexmedetomidine",{"label":15,"type":10,"description":16,"interventionNames":17},"The magnesium sulfate","29 patients will receive 20 mg\u002Fkg as loading dose over 10 minutes before induction then maintenance dose 5 mg\u002Fkg\u002Fhour, which will also be discontinued at the skin closure",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","dexmedetomidine","20 mg\u002Fkg as a loading dose over 10 minutes before induction then a maintenance dose of 5 mg\u002Fkg\u002Fhour, which will also be discontinued at the skin closure.",[9,15],[25],"magnesium sulfate",null,[28],{"name":29,"role":30,"phone":31,"phoneExt":26,"email":32},"Mohamed Ahmed Hamed, MD","CONTACT","01010509736","mah07@fayoum.edu.eg",[34],{"facility":35,"status":36,"city":37,"state":26,"zip":26,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":26},"Dexmedetomidine","RECRUITING","Al Fayyum","Egypt","EG",{"type":41,"coordinates":42},"Point",[43,44],30.8418,29.30995,{"lat":44,"lon":43},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Mohamed Ahmed Hamed","Professor","100570072","phase-1-dexmedetomidine-and-magnesium-sulfate-in-the-reduction-cognitive-dysfunction-in-geriatrics-100570072",false,"NCT06702488","Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics","The Efficacy of Dexmedetomidine and Magnesium Sulfate in Cognitive Dysfunction","Inclusion Criteria:\n\n* ASA physical status I, II and ⅠⅠⅠ\n* patients undergoing open abdominal surgery under general anesthesia\n\nExclusion Criteria:\n\n* Elderly patients with preoperative MoCA Score below 26.\n* Operation time more than 4 hours to prevent excessive dosage of magnesium sulfate.\n* BMI \\> 35 kg m-2","ALL","60 Years","80 Years",{"count":61,"type":62},58,"ESTIMATED","INTERVENTIONAL",[65],"PHASE1","Magnesium sulfate is considered a neuroprotective drug and has been studied in various applications. Recently, it has drawn the attention of anesthesiologists, resulting in numerous publications about its role in anesthesiology.\n\nMagnesium sulfate is suggested to exert its neuroprotective effect by preventing excitotoxicity. in the clinical setting, intraoperative magnesium sulfate attenuated POCD. Furthermore, postoperative emergence agitation was significantly reduced in pediatric patients who received intraoperative magnesium sulfate during adenotonsillectomy.\n\nThe aim of this study The aim of this work is to compare the protective effect of intraoperative dexmedetomidine with magnesium sulfate against developing POCD and to study their effect on serum level of CRP; the marker of neuronal degeneration.",[68],"Mental Disorder",[70],"Post-operative cognitive dysfunction","2024-11-21",{"date":73,"type":74},"2024-11-25","ACTUAL",{"date":71,"type":74},{"date":77,"type":62},"2025-05-15",{"name":5,"class":6},1]